Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Tempus to buy cancer test-maker Personalis for $1.5B
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.